Franco Lombardo Ph. D.
Founder / Principal
CmaxDMPK, LLC
M.S. Pharmaceutical Chemistry and Technology, University of Rome, La Sapienza, Italy
Ph.D. Organic Chemistry, University of Minnesota
(Work experience: Alkermes, Biogen, Novartis, Pfizer and Merck Research Laboratories)
Dr. Lombardo primary interests and areas of expertise reside in ADME/physicochemical properties determination and modeling. As an organic chemist by training, he places particular emphasis and attention on the organic and medicinal chemistry underlying structure-properties relationships. He also has expertise with in vitro, in vivo and in silico tools and approaches and human PK modeling and dose prediction. He has co-authored 49 research publications and book chapters, as well as presented invited lectures and seminars at Universities and industrial conferences worldwide. He is a co-inventor on 5 patents.
After 3 years at Merck Research Laboratories, in the pre-formulation group within Pharmaceutical Research and Development in West Point PA, Dr. Lombardo moved to Pfizer in Groton, CT. He started in the Early Candidates Group in Pharmaceutical Research and Development working on physicochemical and formulation aspects in close contact with Discovery scientists. He then joined Pfizer Discovery in 1998, as a member of the Molecular Properties Group sharing responsibilities with Dr. Chris Lipinski, and focusing on physicochemical properties and their application to ADME, ranging from the development of physicochemical methods to in silico applications.
In 2006 he moved to the Novartis Institutes for Biomedical Research, within the Metabolism and Pharmacokinetics group in Cambridge, MA. His primary work was on PK characterization as project team member and supervisor of the disease area team members largely in Oncology, with responsibilities spanning to Infectious Diseases and Ophthalmology.
In October 2014 he accepted a position at Biogen where he maintained his involvement with, and interest in, PK and physicochemical properties with a very significant ADME modeling component.
As of January 2017 he joined Alkermes as Senior Director and head of the DMPK & Bioanalysis Group, within Clinical Research, with responsibilities spanning Discovery and Development. He holds an Affiliate Research Professorship appointment at Northeastern University Department of Chemistry and Chemical Biology, in Boston, as of August 2019.
In May 2021 Dr. Lombardo founded CmaxDMPK, LLC, to offer consulting and training in ADME/DMPK for small molecules.